Carrie Fijal, MSN, AGPCNP-BC, OCN

Current Trials

• Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma

  HIC ID2000029793RoleSub InvestigatorPrimary Completion Date02/01/2023

  Recruiting Participants

  Lymphoma

• A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma

  HIC ID2000026850RoleSub InvestigatorPrimary Completion Date12/31/2024

  Recruiting Participants

  Gynecological Cancers

• Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk With Radiation (PREDICT-RT*)

  HIC ID2000032279RoleSub InvestigatorPrimary Completion Date12/31/2033

  Recruiting Participants

  Prostate Cancer

• Phase Ib/II Study of ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors and Lymphomas

  HIC ID2000033256RoleSub InvestigatorPrimary Completion Date07/01/2025

  Recruiting Participants

  Phase 1 Cancers

• A Phase 1a/1b Study of LY3537982 in Patients With KRAS G12C-Mutant Advanced Solid Tumors

  HIC ID2000031441RoleSub InvestigatorPrimary Completion Date09/01/2025

  Recruiting Participants

  Phase 1 Cancers